76 results about "Furin" patented technology

Cleavage site for the protease furin is inserted between domains of a membrane glycoprotein. Upon cleavage by furin in the trans-Golgi network, the protein is separated into individual membrane-free domain that retains its native conformation. This protocol can be used to produce virus membrane protein domains for structural analysis and for trials as vaccines.

Disclosed are certain peptide linkers for conjugating drugs to ligands, and the resulting drug-linker-ligand molecules and compositions thereof. The conjugated molecules useful for the targeted delivery of drugs to the desired cells, and allow for the intracellular release of the drug in cases where the targeted antigen is internalized via the trans Golgi network and not the lysosomal pathway.

The present invention relates to a method of treating an individual having a blood coagulation defect (e.g., hemophilia A, hemophilia B), comprising administering to the individual an effective amount of a DNA vector encoding modified Factor VII (FVII), wherein the modified Factor VII leads to generation of Factor VIIa in vivo. In a particular embodiment, the invention pertains to a method of treating an individual having a blood coagulation defect comprising administering to the individual an effective amount of a nucleic acid encoding a modified FVII wherein the modified FVII comprises a signal which codes for precursor cleavage by furin at the activation cleavage site of the modified FVII. The invention also relates to a method of treating an individual having a blood coagulation disorder comprising administering to the individual an effective amount of a nucleic acid encoding the light chain of human FVII and a nucleic acid encoding the heavy chain of human FVII operably linked to a leader sequence. Compositions, expression vectors and host cells comprising nucleic acid which encodes a modified Factor VII, wherein the modified Factor VII leads to generation of Factor VIIa in vivo is also encompassed by the present invention.

The invention provides mutated, cytotoxic forms of Pseudomonas exotoxin A (PE) comprising a furin cleavage sequence conjugated or fused directly to residues 395-613 of PE or variants of that sequence. These minimal forms of PE are smaller than previous cytotoxic forms of PE, reduce non-specific toxicity, and reduce immunogenicity due to domain II or domain Ib of PE. The invention further provides nucleic acids encoding said PEs, chimeric molecules containing them, and methods of use thereof.

The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.

The present invention provides a modified toxin having an ETA moiety that has the furin site replaced with a cancer-associated protease site. The present invention also provides modified immunotoxins having a ligand that binds to a cancer cell attached to an ETA moiety that has the furin site replaced with a cancer-associated protease site. Also provided are a method of inhibiting or destroying mammalian cancer cells using the immunotoxins of the invention and pharmaceutical compositions for treating human cancer.

The invention provides a novel coronavirus mutant strain S protein and a subunit vaccine thereof. The novel coronavirus mutant strain S protein is characterized in that a furin cleavage site 682-RRAR-685 between an S1 subunit and an S2 subunit of the novel coronavirus mutant strain S protein is replaced with a flexible protein linker; the linker is (GGCAGCGCCAGC), or (GGCGGCGGCAGC)n, or (GGCGGCGGCGGCAGC)n, or (GGC)n, or the linker is GSAS or (GGGS)n or (GGGGS)n or (G) n, n is greater than or equal to 1 and less than or equal to 3, and n is an integer; and the amino acid sequence of the novel coronavirus mutant strain S protein is as shown in SEQ ID NO: 2 or as shown in SEQ ID NO: 4. The S protein has great potential as a vaccine antigen for coping with an SARS-CoV-2 mutant strain.

Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC(TM) resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC(TM) chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.

The present invention relates to recombinant furin (rFurin) and methods for producing rFurin. More specifically, the invention relates to substantially animal protein-free rFurin and methods for producing substantially animal protein-free rFurin.

This patent discloses compositions and methods of use thereof to normalize the blood glucose levels of patients with type 2 diabetes. It relates particularly to a plasmid comprising a chicken beta actin promoter and enhancer; a modified GLP-1 (7-37) cDNA (pbetaGLP1), carrying a furin cleavage site, which is constructed and delivered into a cell for the expression of active GLP-1.

The invention provides a respiratory syncytial virus pre-fusion F protein and application thereof, and belongs to the technical field of respiratory syncytial virus vaccines. The pre-fusion F proteinis formed in the way that the 106th, 108th and 109th amino acids of a wild-type F protein are mutated from Arg to Asn, the 104th amino acid is mutated from Asn to Cys, the 155th amino acid is mutatedfrom Ser to Cys, or the 58th amino acid is mutated from Thr to Cys, and the 190th amino acid is mutated from Ser to Cys. A first furin cleavage site of the mutant wild-type F protein makes the structure of Pre-F more stable, the expression amount is not decreased, and the pre-fusion epitope of M1-F expression in 293T cells is significantly increased. The second mutation of the amino acid site of the F protein forms a disulfide bond, achieves the more stable pre-fusion epitope compared to the wild type, and is suitable for other strains of human RSV. The protein is suitable for various vaccineforms with the RSV F protein as the antigen, such as nucleic acid vaccines, protein vaccines, vector vaccines and recombinant virus particle vaccines.

The present invention provides minigenes suitable as a prophylactic or therapeutic vaccine against conditions such as cancer, infectious diseases or autoimmune diseases, and pharmaceutical compositions comprising the minigene. The minigenes of the present invention comprise (a) a human tissue plasminogen signal peptide; (b) at least one T-cell epitope; and (c) an E. coli heat labile enterotoxin B subunit; wherein the at least one T-cell epitope is linked to the rest of the minigene, and to any other epitopes, by furin sensitive linkers. In some embodiments of the invention, the minigene comprises T-cell epitopes from one or more of CEA, her-2/neu and hTERT. Also provided herein are immunogenic peptide epitopes of CEA, her-2/neu and hTERT, as well as immunogenic peptide analogs, and pharmaceutical compositions and vaccines comprising one or more of said peptides and analogs for prophylaxis and/or treatment of cancer or other disorder. Methods of inducing an immune response in a patient, in addition to methods of treatment using the minigenes, immunogenic peptides, and peptide analogs disclosed herein are also provided.

The present invention provides compositions and methods for inhibiting abnormal cell growth. In particular, the invention provides nucleic acids encoding Diphtheria toxin fusion proteins comprising residues 1-388 of Diphtheria toxin, wherein the native furin cleavage site has been substituted for a matrix metalloproteinase or plasminogen activator cleavage site, and a heterologous polypeptide and the polypeptides encoded by such nucleic acids. In addition, the invention provides methods of treating cancer by administering such polypeptides.

The present invention includes compositions and methods for cancer treatment. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-ss through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.

The present invention relates to a method for diagnosis and/or prognosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a subject by determining the molecular form of cadherin at the cell surface of cancer cells in the subject. The invention also relates to a method for preventing, inhibiting or treating cancer or its metastasis in a subject by increasing the adhesive forms of cadherin and/or decreasing the non-adhesive forms of cadherin at the cell surface. The invention also relates to a method step of determining the expression level of furin and proprotein convertase 5A (PC5A).

The invention discloses a lentivirus expression vector of an anti-p185erdB2 human mouse chimeric antibody containing an F/2A sequence, and a construction method of the lentivirus expression vector. Furin or foot and mouth disease virus/2A polypeptide (F/2A) with self shearing capacity is connected with a heavy chain and a light chain of the human-mouse chimeric antibody to form an open reading frame (ORF), and the ORF is inserted into a lentivirus expression vector pWPI to construct the expression vector pWPI/H-F2A-L of the recombination anti-p185erdB2 overall-length human mouse chimeric antibody. According to sequencing identification, the pWPI/H-F2A-L is consistent to expected design. The infection efficiency of recombination lentivirus is 87.68%, and the expressions of the chimeric heaving chain and light chain are formed after the recombination lentivirus is infected with 293T cells. Compared with that of a lentivirus expression vector of an IRES (Internal Ribosome Entry Site) chimeric antibody, the expression level of the chimeric antibody mediated by the F/2A is higher than that of the chimeric antibody mediated by IRES, thereby laying a foundation for research on anti-p185erdB2 engineering antibodies.

The invention discloses a lentiviral expression vector, as well as a preparation method and an application of the lentiviral expression vector, and a preparation method of a recombinant lentivirus. The lentiviral expression vector is a pRRLSIN.cPPT.MSCV-Dual.WPRE vector, which is obtained by replacing the GFP sequence of a pRRLSIN.cPPT.MSCV/GFP.WPRE vector with a double gene expression box Dual, wherein the double gene expression box Dual comprises the following structure sequentially arranged from the 5' terminal to the 3' terminal: a first polyclonal site-a furin cleavage site-a V5 label-Spacer-2A peptide-a second polyclonal site, the mark '-' represents the connection relation. According to the lentiviral expression vector, 2A peptide is utilized for realizing the expression of double exogenous genes in cells of mammals, 2A peptide has the 'self-shearing' property, in the translation process of protein, 2A peptide changes the activity of ribosome, promotes the hydrolysis of ester chains between peptide residue Gly and tRNAGly of 2A, releases upstream polypeptides and starts the translation of upstream polypeptides from a transcribed compound, and the realizes double gene expression in the level of translation.

The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.